Matthew French, MD
Surgery · Covington, LANPI 1609837087
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Flexdex Inc. at 40.6% of the total. Reporting peaked in 2023 at $6,294 and has fallen 96.1% since, to $243 in 2025.
Across 93 payments — averaging $129.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Flexdex Inc.$5K
- Intuitive Surgical$4K
- Centinel Spine, LLC$860
- Johnson & Johnson$489
- Ambu Inc.$410
- Takeda Pharmaceuticals U.S.A., Inc.$322
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$4,90041%
- Travel & lodging$1,75915%
- Food & beverage$2,92224%
- Education$2,50021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Flexdex Inc. | 1 | $4,900 |
| Intuitive Surgical | 10 | $3,685 |
| Centinel Spine, LLC | 6 | $860 |
| Johnson & Johnson | 6 | $489 |
| Ambu Inc. | 3 | $410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $322 |
| Medtronic | 3 | $296 |
| Novo Nordisk | 14 | $266 |
| Echosens North America, Inc. | 1 | $116 |
| Shire North American Group Inc | 6 | $89 |
| Baxter Healthcare | 2 | $83 |
| Hologic Sales And Service, LLC | 2 | $77 |
| Intra-sana Laboratories | 3 | $76 |
| Covidien LP | 1 | $54 |
| Stryker | 1 | $52 |
| Asensus Surgical, Inc. | 1 | $43 |
| Boston Scientific | 2 | $34 |
| Innovation Technologies Inc | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
| Reshape Lifesciences Inc. | 1 | $20 |
| Nalpropion Pharmaceuticals LLC | 1 | $19 |
| Vertex | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| KCI USA, Inc. | 1 | $16 |
| TELA Bio, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Kvk-tech, Inc. | 1 | $14 |
| Innocoll Pharmaceuticals Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$2,500
- Da Vinci Surgical System$1,012
- PRODISC C VIVO$518
- ECHELON FLEX Stapler$247
- PRODISC L$208
- Signia$193
- Echelon Flex$127
- HARMONIC Product Family$123
- FibroScan$116
- LINX Reflux Management System$107
How this compares
$12,081 in reported general payments places this provider in the 85th percentile of 381 surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 24 | $1,434,552 |
| OzempicSemaglutide | 39 | $45,916 |
| MounjaroTirzepatide | 36 | $40,963 |
| CreonLipase/Protease/Amylase | 11 | $10,983 |
| Sucralfate | 39 | $5,460 |
| Esomeprazole Magnesium | 53 | $1,479 |
| Pantoprazole Sodium | 129 | $588 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 25 | $322 |
| Ondansetron OdtOndansetron | 16 | $250 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $134 |
| Omeprazole | 12 | $96 |
| Lansoprazole | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $322 | $1,434,55224 claims |
| Novo NordiskOzempic | $266 | $45,91639 claims |
| Lilly USA, LLCMounjaro | $20 | $40,96336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 surgery providers in Louisiana.
Other surgery in Covington
- Ralph CorsettiCovington$29K
- James RedmannCovington$21K
- Jacob DaigleCovington$14K
- John TaborBaton Rouge$567K
- Carlos GalvaniNew Orleans$352K
- Mark HausmannBaton Rouge$250K
- Joseph BuellNew Orleans$186K
- Daryl MarxBaton Rouge$157K
- Matias NautsLake Charles$112K
- Tracee ShortBaton Rouge$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.